Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Not yet recruiting 2 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Specimen Handling 16 Biopsy 11 Magnetic Resonance Spectroscopy 10 Taxes 4 Bevacizumab 4 Cyclophosphamide 3 Cetuximab 3 olaparib 2 decitabine and cedazuridine drug combination 2 Vincristine 2 Prednisone 2 Paclitaxel 2 Immunoglobulin G 2 Gemcitabine 2 Doxorubicin 2 Disulfides 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 (225)Ac-DOTA-c(RGDyK) 2 zimberelimab 1 zanubrutinib 1 trastuzumab deruxtecan 1 taletrectinib 1 spartalizumab 1 sotigalimab 1 relatlimab 1 regorafenib 1 prednylidene 1 neratinib 1 mirdametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × IFL protocol × 30 days × Clear all

NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡